DrugPatentWatch Database Preview
Drugs in Development Information for Samatasvir
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Samatasvir?
Samatasvir is an investigational drug.
There have been 5 clinical trials for Samatasvir.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2013.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Janssen Research & Development, LLC, and [disabled in preview].
There are two US patents protecting this investigational drug and seventeen international patents.
Summary for Samatasvir
| US Patents | 2 |
| International Patents | 17 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-03-01) |
| Vendors | 1 |
Recent Clinical Trials for Samatasvir
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) | Merck Sharp & Dohme Corp. | Phase 1 |
| Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) | Janssen Research & Development, LLC | Phase 2 |
| Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) | Merck Sharp & Dohme Corp. | Phase 2 |
Clinical Trial Summary for Samatasvir
Top disease conditions for Samatasvir
Top clinical trial sponsors for Samatasvir
US Patents for Samatasvir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Samatasvir | Start Trial | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | Idenix Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Samatasvir | Start Trial | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | Idenix Pharmaceuticals LLC (Cambridge, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Samatasvir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Samatasvir | Argentina | 079528 | 2029-12-18 | Start Trial |
| Samatasvir | Australia | 2010330862 | 2029-12-18 | Start Trial |
| Samatasvir | Brazil | 112012014899 | 2029-12-18 | Start Trial |
| Samatasvir | Canada | 2784748 | 2029-12-18 | Start Trial |
| Samatasvir | China | 102822175 | 2029-12-18 | Start Trial |
| Samatasvir | European Patent Office | 2513113 | 2029-12-18 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
